Bayesian Capital Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Bayesian Capital Management’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-10,700	Closed	-$34.7K	–	671
2024 Q3	$34.7K	Buy	+10,700	New	+$24.1K	﹤0.01%	632
2023 Q3	–	Sell	-10,050	Closed	-$217K	–	683
2023 Q2	$217K	Sell	10,050 -6,300	-39%	-$170K	0.02%	624
2023 Q1	$480K	Buy	16,350 +1,650	+11%	+$57.3K	0.06%	402
2022 Q4	$543K	Buy	+14,700	New	+$522K	0.08%	331

Other funds holding AMLX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

Bayesian Capital Management's AMLX Position: Q4 2024 in Review

Bayesian Capital Management sold out of Amylyx Pharmaceuticals (AMLX) in Q4 2024, closing a stake of 10,700 shares — an estimated $34.7K sold.

Bayesian Capital Management first reported a position in AMLX in Q4 2022 and held it in 4 quarters. The position peaked at $543K in Q4 2022. 122 funds tracked by Wall St. Rank hold AMLX as of Q4 2024.

Bayesian Capital Management reported no remaining Amylyx Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Bayesian Capital Management sold 10,700 Amylyx Pharmaceuticals shares in Q4 2024, an estimated $34.7K.
Bayesian Capital Management first reported a position in Amylyx Pharmaceuticals in Q4 2022 and held it in 4 quarters.
Bayesian Capital Management's Amylyx Pharmaceuticals position peaked at $543K in Q4 2022.
122 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q4 2024.

Based on Bayesian Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.